ArticleAllergy2026
The Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE-D Study.
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study.American journal of clinical dermatology · 2026Article
- Clinical Factors Associated with Disease Severity in Symptomatic Dermographism: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- Guideline-recommended inflammatory testing in symptomatic dermographism: a real-world study.Frontiers in immunology · 2026Article
- Dermographism in chronic spontaneous urticaria: associations with disease activity, autoimmunity, and disease duration.Frontiers in immunology · 2026Observational
- Beyond Antihistamines: How Biologic and Small-Molecule Therapies Are Transforming Chronic Spontaneous Urticaria Care in Adults.Clinical drug investigation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
56 authors.
Funding
Abstract
backgroundThe prevalence of symptomatic dermographism (SD) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes-physiological red dermographism and simple urticarial dermographism-among adults worldwide.
methodsThe PREVALENCE-D (Prevalence Estimation of Dermographism) study was the largest international, cross-sectional, internet-based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert-designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD. Participants were recruited into three age groups (18-24, 25-60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex- and age-adjusted prevalence estimates internationally and by country, with 95% confidence intervals.
resultsAmong 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [CI] 2.68%-3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%-6.56%). The 25-60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%-10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%-34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%-1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%-5.79%).
conclusionThese findings provide comprehensive international estimates of dermographism, particularly SD, and emphasize the need for appropriate healthcare resource allocation and disease recognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.